Plain Language Summary {#Sec1}
======================

Chronic obstructive pulmonary disease (COPD) describes a group of lung conditions characterized by the narrowing of airways, which cause progressive breathing difficulties and persistent symptoms of breathlessness. COPD causes irreversible lung damage; however, numerous treatment options can alleviate symptoms and improve patients' quality of life. Inhaled long-acting bronchodilators are the mainstay of COPD medication as they open the airways to reduce chronic symptoms. In addition, inhaled corticosteroids (ICS) can help reduce airway inflammation, and, in combination with long-acting β~2~-agonist bronchodilator (LABA) therapy, reduce the added risk of acute exacerbations (acute worsening of symptoms requiring additional medical care). The ICS/LABA combination may be combined with a long-acting muscarinic antagonist (LAMA) bronchodilator in patients with severe COPD.

The benefits of using two bronchodilators with complimentary efficacy in combination with ICS was explored in this study, looking at the incidence of clinically important deterioration (CID). CID is a new exploratory measure of deterioration, which examines different types of significant worsening in lung function, patient health status and exacerbation events. This study assessed whether CID events can be prevented by adding once-daily LAMA umeclidinium (UMEC) to the treatment of patients remaining symptomatic on ICS/LABA combination therapy.

We found that the risk of a first CID event of any type was reduced by approximately half in symptomatic patients receiving UMEC + ICS/LABA compared with placebo + ICS/LABA therapy, with particular benefits in stabilizing the patients' risk of future lung function deteriorations and reducing acute exacerbations.

Introduction {#Sec2}
============

Chronic obstructive pulmonary disease (COPD), a frequently progressive disease characterized by persistent airflow obstruction, represents a major contributor to global morbidity and mortality \[[@CR1]--[@CR3]\]. A high symptom burden in patients with COPD, in particular high levels of dyspnea with or without frequent use of short-acting rescue medication, is associated with poor quality of life (QoL), increased risk of exacerbations, and a substantial increase in the economic burden of the disease \[[@CR4]--[@CR8]\].

The mainstay of pharmacotherapy for COPD is bronchodilation with a long-acting muscarinic antagonist (LAMA), a long-acting β~2~-agonist (LABA), or a combination of the two \[[@CR9], [@CR10]\]. For patients with a high symptom burden and a history of exacerbations, a recommended \[[@CR1]\] and relatively common \[[@CR11]--[@CR13]\] therapeutic approach is the co-administration of a LAMA, a LABA, and an ICS as triple therapy. This approach has demonstrated reductions in the risks of hospitalization and all-cause mortality when compared with ICS/LABA combination therapy in large, non-randomized cohort studies \[[@CR11], [@CR14]\].

The efficacy of the LAMA and ICS/LABA components of triple therapy versus placebo have been well demonstrated in randomized controlled trials (RCTs) \[[@CR15], [@CR16]\]. Available data from RCTs of triple therapy have demonstrated improvements in lung function and health status and reduced use of rescue medication, with no increased safety concerns, in symptomatic patients receiving additional bronchodilation with a LAMA added to ICS/LABA therapy compared with those continuing ICS/LABA therapy alone \[[@CR17], [@CR18]\]. More recently, limited data from RCTs have demonstrated that the addition of a LAMA to ICS/LABA therapy reduces exacerbation incidence \[[@CR19], [@CR20]\]. However, the impact of adding additional bronchodilation with a LAMA to symptomatic patients using ICS/LABA therapy to maintain disease stability beyond preventing exacerbations is not well understood.

According to the Global initiative for chronic Obstructive Lung Disease (GOLD) report, the goals of the management of COPD are to reduce daily symptoms and to reduce the future risk of poor outcomes \[[@CR1]\]. One key component of achieving these goals is to ensure optimal disease management by regular monitoring of patients to assess the adequacy of their current therapy in maintaining lung function stability and symptom control, as well as minimizing the incidence of exacerbations \[[@CR1]\]. Clinical trials in COPD usually evaluate improvements in spirometry, symptoms and QoL. However, improvements in these parameters are not always observed, and many patients may not respond to treatment \[[@CR21]\] and can experience deterioration of their disease without the occurrence of acute exacerbations. It is therefore important to assess both improvement and deterioration so that levels of disease stability and instability in patients receiving any new treatment can be quantified; this approach is consistent with the management goals set out in the GOLD report \[[@CR1]\].

In order to compare the effects of therapies on short-term stability, a novel composite endpoint assessing three dimensions of CID (lung function, health status, and exacerbations) has been described \[[@CR22]\]. This composite endpoint has been used to demonstrate improved stability after increasing bronchodilation in symptomatic patients using dual fixed-dose LAMA/LABA combination therapies compared with placebo, ICS/LABA therapy or LAMA or LABA monotherapies \[[@CR21]--[@CR23]\].

To build upon these results, this integrated post hoc analysis of four short-term double-blind efficacy trials of replicate design aimed to assess the impact of providing additional bronchodilation with the LAMA umeclidinium (UMEC) versus placebo in preventing CIDs in patients who remained symptomatic on ICS/LABA therapy. A previous integrated post hoc analysis of the four studies included in this analysis demonstrated improvements in lung function and QoL, and reduced rescue medication use, in patients using ICS/LABA therapy who received additional bronchodilation with UMEC versus placebo \[[@CR18]\]. This analysis will assess whether the improvements observed in these outcomes will translate to improved stability and reductions in short-term CIDs.

Methods {#Sec3}
=======

Study Design {#Sec4}
------------

This was an integrated post hoc analysis (GSK study number: 202067) of four 12-week, Phase III, multicenter, randomized, double-blind, parallel-group trials comparing UMEC + ICS/LABA with placebo + ICS/LABA \[[@CR24], [@CR25]\]. Once-daily UMEC (62.5 or 125 µg) or placebo were administered double-blind via the ELLIPTA dry powder inhaler (DPI). The ICS/LABA combinations investigated were twice-daily fluticasone propionate/salmeterol (FP/SAL) 250/50 µg administered via the DISKUS DPI (trials AC4116135 \[NCT01772134\] and AC4116136 \[NCT01772147\]) \[[@CR24]\] and once-daily fluticasone furoate/vilanterol (FF/VI) 100/25 µg administered via the ELLIPTA DPI \[trials 200109 (NCT01957163) and 200110 (NCT02119286)\] \[[@CR25]\]. ELLIPTA and DISKUS are owned by or licensed to the GSK group of companies.

All studies had a replicate design, as previously reported \[[@CR24], [@CR25]\], whereby enrolled patients entered a 4-week open-label run-in treatment period with once- or twice-daily ICS/LABA. At the end of this period, patients without a COPD exacerbation, who did not use any prohibited medications, and who were 80--120% compliant with the open-label ICS/LABA were randomized to receive additional bronchodilation with UMEC or matching placebo added to their ICS/LABA treatment for a further 12 weeks. Only the results from the approved dose of UMEC (62.5 µg) \[[@CR26], [@CR27]\] are presented here. In the original studies, the two doses of UMEC were shown to have similar efficacy and safety profiles when added to ICS/LABA therapy \[[@CR24], [@CR25]\].

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. The study presented was an integrated post hoc analysis of four clinical trials all conducted in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. All participants provided written informed consent before participation in the studies considered in this analysis.

Patients {#Sec5}
--------

Key inclusion criteria for all studies included in this analysis were as follows \[[@CR24], [@CR25]\]: patients ≥ 40 years of age with an established clinical history of COPD in accordance with the American Thoracic Society/European Respiratory Society definition \[[@CR28]\], classified as Group B or D according to the GOLD 2016 strategy document \[[@CR29]\]; a current or former smoker with a smoking history of ≥ 10 pack-years; a predicted post-bronchodilator forced expiratory volume in 1 s (FEV~1~) of ≤ 70%; a FEV~1~/forced vital capacity ratio of \< 0.70 at first visit; and a score of ≥ 2 on the modified Medical Research Council (mMRC) dyspnea scale at first visit. Key exclusion criteria included \[[@CR24], [@CR25]\]: a diagnosis of asthma or another known clinically relevant respiratory disease (other than COPD); and hospitalization for COPD or pneumonia in the 12 weeks prior to first visit.

Outcomes and Assessments {#Sec6}
------------------------

The primary endpoint for all four studies was trough FEV~1~ on day 85 in the intent-to-treat (ITT) population. Other endpoints included: St George's Respiratory Questionnaire (SGRQ) total score; incidence of exacerbations (defined as any acute worsening of COPD symptoms requiring the use of antibiotics, systemic corticosteroids, emergency treatment or hospitalization); and the proportions of patients achieving improvements of ≥ 100 mL in trough FEV~1~ or ≥ 4 units in SGRQ score, respectively. Adverse events (AEs) after the run-in period were assessed in all studies; AEs of special interest included those associated with the use of LAMAs.

A first CID was defined as any of the following: decrease of ≥ 100 mL from baseline in trough FEV~1~; increase of ≥ 4 units in SGRQ total score from baseline; or a moderate/severe exacerbation. In this analysis, the risk of a first CID of each type and a first composite CID were evaluated in the ITT population, and in patients stratified by GOLD Group B and D, exacerbation history at screening and type of ICS/LABA therapy. AEs are presented for the pooled ITT populations.

Statistical Analyses {#Sec7}
--------------------

The time to the first deterioration based on the composite endpoint was taken as the time to the first deterioration event of any component. Hazard ratios (HR), 95% confidence intervals (CIs) and *p* values for the treatment comparisons of UMEC + ICS/LABA versus placebo + ICS/LABA were calculated based on the time to first event using a Cox proportional hazards model with covariates of treatment, study and smoking status at screening. Kaplan--Meier survivor functions of the proportion of subjects with deterioration over time were obtained separately for each treatment group. Statistical analyses were performed using SAS v.9 (SAS Institute, Cary, NC, USA).

Results {#Sec8}
=======

Baseline Characteristics {#Sec9}
------------------------

In total, 1637 patients were randomized to UMEC 62.5 µg + ICS/LABA (*n* = 819) or placebo + ICS/LABA (*n* = 818) and received at least one dose of study medication (ITT population). Patient demographics and baseline characteristics were similar across the two treatment groups (Table [1](#Tab1){ref-type="table"}), with mean \[standard deviation (SD)\] ages of 63.7 (8.3) and 64.1 (8.4) years in the UMEC + ICS/LABA and placebo + ICS/LABA groups, respectively. The majority of patients in both the UMEC + ICS/LABA and placebo + ICS/LABA groups were male (67% and 64%, respectively) and classified as GOLD Group D according to the GOLD 2016 classifications \[[@CR29]\] (61% and 58%, respectively). Patient clinical characteristics were also similar across the two treatment groups (Table [1](#Tab1){ref-type="table"}).Table 1Baseline demographics and clinical characteristics (ITT population).Adapted from: Siler et al. \[[@CR18]\]CharacteristicsUMEC 62.5 µg + ICS/LABA (*n* = 819)Placebo + ICS/LABA (*n* = 818)Age, years63.7 (8.3)64.1 (8.4)Male, *n* (%)547 (67)521 (64)Current smoker at screening^a^, *n* (%)376 (46)402 (49)Smoking history, pack-years^b^47.8 (26.2)47.6 (25.6)Baseline pre-bronchodilator FEV~1~, L1.26 (0.47)1.27 (0.48)^c^ GOLD B patients1.59 (0.42)1.60 (0.44) GOLD D patients1.05 (0.37)1.03 (0.35)Post-albuterol % predicted FEV~1~45.3 (12.4)46.4 (13.0)Reversible patients^d^, *n* (%)265 (32)^e^235 (29)GOLD group^f^, *n* (%) B320 (39)344 (42) D499 (61)474 (58)  With FEV~1~ \< 50% predicted, *n* (%)478 (96)464 (98)  With FEV~1~ \< 30% predicted, *n* (%)94 (19)108 (23)  With ≥ 1 exacerbations^g^, *n* (%)122 (24)115 (24)  With ≥ 2 exacerbations^g^, *n* (%)46 (9)32 (7)Moderate exacerbations^g^ in 12 months prior to screening, *n* (%)160 (20)162 (20)Puffs of albuterol per day^h^2.2 (2.8)2.0 (2.5)SGRQ total score44.6 (17.2)44.6 (17.5)ICS/LABA treatment during run-in, *n* (%) FF/VI412 (50)412 (50) FP/SAL407 (50)406 (50)Values are reported as mean (SD) unless otherwise stated*FEV*~*1*~ forced expiratory volume in 1 s, *FF* fluticasone furoate, *FP* fluticasone propionate, *GOLD* Global initiative for chronic Obstructive Lung Disease, *ICS* inhaled corticosteroid, *ITT* intent-to-treat, *LABA* long-acting β~2~-agonist, *mMRC* modified Medical Research Council, *SAL* salmeterol, *SD* standard deviation, *SGRQ* St George's Respiratory Questionnaire, *UMEC* umeclidinium, *VI* vilanterol^a^Smoked within 6 months^b^Smoking history defined as (number of cigarettes smoked per day/20) × number of years smoked^c^*n* = 815^d^Reversibility defined as increase in FEV~1~ of ≥ 12% and ≥ 200 mL following administration of albuterol^e^*n* = 818^f^Classified by criteria presented in GOLD 2016 update \[[@CR29]\] using mMRC ≥ 2 as the criterion for high symptom burden; definition included percent predicted FEV~1~ as a severity marker (i.e., patients could be included in Group D with an FEV~1~ \< 50% predicted)^g^Exacerbations defined as those requiring oral/systemic corticosteroids and/or antibiotics, but not involving hospitalization^h^Mean puffs/day during last 7 days of run-in

Incidence of CIDs {#Sec10}
-----------------

The proportion of patients in the ITT population experiencing any CID was higher in the placebo + ICS/LABA group than in the UMEC + ICS/LABA group (68% vs. 46%; Fig. [1](#Fig1){ref-type="fig"}a). For both any CID and risk of first CID event, the most common cause of deterioration in the ITT population and patients stratified by subgroup analyses were FEV~1~ CID events in the placebo + ICS/LABA group and SGRQ CID events in the UMEC + ICS/LABA group; the least common was exacerbation CID events in both treatment groups (Figs. [1](#Fig1){ref-type="fig"}a, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}; Supplementary Fig. 1).Fig. 1Analysis of CIDs in the ITT population. **a** Type of deterioration; **b** Kaplan--Meier plot of time to first composite CID. \*HR and 95% CI based on a time to first event analysis using a Cox's proportional hazards model. *CI* confidence interval, *CID* clinically important deterioration, *FEV*~*1*~ forced expiratory volume in 1 s, *HR* hazard ratio, *ICS/LABA* inhaled corticosteroid/long-acting β~2~-agonist, *SGRQ* St George's Respiratory Questionnaire, *UMEC* umeclidinium Fig. 2Analysis of CIDs stratified by GOLD 2016 groups^a^. ^a^Classified by criteria presented in GOLD 2016 update \[[@CR29]\]; definition included percent predicted FEV~1~ as a severity marker (i.e., patients could be included in Group D with an FEV~1~ \< 50% predicted). \*HR and 95% CI based on a time to first event analysis using a Cox's proportional hazards model. *CI* confidence interval, *CID* clinically important deterioration, *FEV*~*1*~ forced expiratory volume in 1 s, *HR* hazard ratio, *ICS/LABA* inhaled corticosteroid/long-acting β~2~-agonist, *SGRQ* St George's Respiratory Questionnaire, *UMEC* umeclidinium Fig. 3Analysis of CIDs stratified by exacerbation history^a^. ^a^Exacerbation-free patients were defined as those with no history of exacerbations requiring oral/systemic corticosteroids and/or antibiotics. \*HR and 95% CI based on a time to first event analysis using a Cox's proportional hazards model. *CI* confidence interval, *CID* clinically important deterioration, *FEV*~*1*~ forced expiratory volume in 1 s, *HR* hazard ratio, *ICS/LABA* inhaled corticosteroid/long-acting β~2~-agonist, *SGRQ* St George's Respiratory Questionnaire, *UMEC* umeclidinium

Risk of a First CID {#Sec11}
-------------------

### ITT Population {#Sec12}

At any given time point, the probability of patients experiencing a CID was lower for patients receiving UMEC + ICS/LABA than those receiving placebo + ICS/LABA (Fig. [1](#Fig1){ref-type="fig"}b). In the ITT population, the risk of a first CID of any type was reduced by 48% (95% CI 41, 55; *p* \< 0.001) in patients stepping up to UMEC + ICS/LABA compared with placebo + ICS/LABA (Fig. [1](#Fig1){ref-type="fig"}a). Significant reductions in the risk of a first CID were observed in patients receiving additional bronchodilation with UMEC for both FEV~1~ events \[69% (95% CI 62, 74) risk reduction; *p* \< 0.001\] and exacerbation events \[47% (95% CI 18, 66) risk reduction; *p* = 0.004\]. However, the reduction in the risk of a SGRQ CID was not significant \[15% (95% CI − 2, 28) risk reduction; *p* = 0.074\].

### Patients Stratified by GOLD 2016 Group B and D {#Sec13}

Addition of UMEC to ICS/LABA therapy significantly reduced the risk of a composite first CID in patients classified as GOLD Groups B and D according to the classifications in the 2016 guidelines \[[@CR29]\] (Fig. [2](#Fig2){ref-type="fig"}). The magnitudes of the reductions in risk of experiencing a composite CID or a CID of any component of the composite endpoint were generally similar between the patients in GOLD Groups B and D. Significant reductions in the risk of a first CID were observed in patients receiving additional bronchodilation with UMEC therapy in both GOLD groups for FEV~1~ events (*p* \< 0.001) and in patients in the GOLD Group D for exacerbation events (*p* = 0.012); however, no significant reduction in the risk of a SGRQ event was observed in patients in either GOLD group.

### Patients Stratified by Exacerbation History {#Sec14}

Addition of UMEC to ICS/LABA therapy significantly reduced the risk of a composite first CID in patients with a history of exacerbations and in those with no prior exacerbations in the 12 months prior to screening (Fig. [3](#Fig3){ref-type="fig"}). The magnitudes of the reductions in risk of experiencing a composite CID or a CID of any component of the composite endpoint were similar in patients with and without a history of exacerbations. However, the reduction in risk of a first exacerbation CID event with additional bronchodilation with UMEC was only statistically significant in patients with a prior exacerbation history (*p* = 0.035). Significant reductions in the risk of a first CID with additional UMEC therapy were also observed in patients with and without a history of exacerbations for FEV~1~ events (*p* \< 0.001); however, no significant reduction in the risk of a SGRQ event was observed in either subgroup.

### Patients Stratified by Type of ICS/LABA Therapy {#Sec15}

The reductions in the risk of a composite CID, and in the risk of a CID of any type, observed with additional bronchodilation with UMEC therapy were generally consistent between patients receiving once-daily FF/VI and those receiving twice-daily FP/SAL (Supplementary Fig. 1). Significant reductions in the risk of a first CID with UMEC + ICS/LABA versus placebo + ICS/LABA were observed in patients receiving both FF/VI and FP/SAL for FEV~1~ events (*p* \< 0.001) and in patients receiving FF/VI for exacerbation events (*p* = 0.033); however, no significant reduction in the risk of a SGRQ event was observed in either ICS/LABA subgroup.

Safety {#Sec16}
------

As previously reported \[[@CR18]\], the incidence of any on-treatment AEs in the ITT population was similar between the two treatment groups (UMEC + ICS/LABA: 36%; placebo + ICS/LABA: 38%). Likewise, incidences of serious AEs (SAEs; non-fatal and fatal; any event) were low and similar between the two treatment groups (non-fatal SAEs: 2% vs. 4%; fatal SAEs: \< 1% vs. \< 1%, for UMEC + ICS/LABA and placebo + ICS/LABA, respectively). The most commonly reported AEs (by ≥ 3% of patients) were nasopharyngitis (UMEC + ICS/LABA: 4%; placebo + ICS/LABA: 6%), headache (UMEC + ICS/LABA: 4%; placebo + ICS/LABA: 4%), and back pain (UMEC + ICS/LABA: 3%; placebo + ICS/LABA: 2%). The incidences of AEs of special interest \[pneumonia, lower respiratory tract infection (LRTI) excluding pneumonia and cardiovascular events\] in patients receiving UMEC were similar to or lower than those in the group receiving placebo (pneumonia: \< 1% vs. 1%; LRTI excluding pneumonia: \< 1% vs. \< 1%; cardiovascular events: 2% vs. 4%, respectively).

Discussion {#Sec17}
==========

Escalation of bronchodilator treatment in patients who remain symptomatic on ICS/LABA is a common treatment strategy for COPD \[[@CR1]\]. Improvements in lung function and health status with additional bronchodilation with UMEC added to ICS/LABA combination therapy compared with ICS/LABA therapy alone have been previously reported \[[@CR18]\]. The results of this complementary integrated retrospective analysis now demonstrate that, compared with placebo, the additional bronchodilation afforded by the addition of UMEC to ICS/LABA combination therapy reduced the short-term risk of clinically important worsening in lung function and exacerbations in patients with persistent symptomatic moderate-to-severe COPD. These improvements in stability were consistent between patients in different GOLD groups (based upon the definition in the 2016 report \[[@CR29]\]), patients with and without a history of exacerbations, and patients receiving either the ICS/LABA combination FF/VI once daily or FP/SAL twice daily.

As a full interpretation of the composite CID endpoint requires examination of the individual component events, we examined the impact of treatment on all three components of the CID: loss of lung function, decline in health status, and incidence of exacerbations. Of these components, it was observed that additional bronchodilator therapy with UMEC had the greatest impact on reducing the risk of deteriorations in trough FEV~1~ in all subgroups of patients (63--78% reduction). Reductions in the risk of a first moderate/severe exacerbation were also observed with UMEC + ICS/LABA therapy versus placebo + ICS/LABA across the overall population and in all subgroups analyzed (39--59% reduction). The magnitude of risk reductions was similar across the subgroups; however, statistical significance was not always observed, for example, in patient subgroups with a low risk of exacerbation and/or FEV~1~ ≥ 50% predicted normal. No statistically significant impact of additional bronchodilation with UMEC therapy on the reduction in deterioration in health status assessed by SGRQ total score was observed in the overall population or any subgroup over the short assessment period.

A relationship between incidence of short--term deteriorations and poorer long--term outcomes has been demonstrated using data from several long-term studies, including the TORCH (NCT00268216) \[[@CR16], [@CR30]\], ECLIPSE (NCT00292552) \[[@CR31]\], and UPLIFT (NCT00144339) \[[@CR15]\] trials \[[@CR32], [@CR33]\]. These post hoc prognostic analyses have consistently shown that patients who experience short-term CID events are at a higher risk of future severe exacerbations and mortality. The enhanced short-term stability reported here may therefore highlight important long-term benefits of providing additional bronchodilation with UMEC + ICS/LABA therapy compared with ICS/LABA alone in symptomatic patients. These benefits also likely explain the improvements in exacerbation outcomes recently reported in 6- to 12-month trials comparing single-inhaler triple therapy with ICS/LABA alone in patients who were symptomatic and at increased risk of future exacerbations or with severe lung function impairment \[[@CR19], [@CR20]\].

The results in this study are similar to those reported in two recent analyses: a post hoc analysis of the TRILOGY study (NCT01917331) \[[@CR20]\] which reported reduced risk of a composite CID with the addition of the LAMA glycopyrronium bromide to the ICS/LABA beclomethasone dipropionate/formoterol fumarate \[[@CR34]\]; and the first prospective CID analysis in the FULFIL study (NCT02345161) \[[@CR19]\], which reported a reduced risk of a composite CID and of all individual components (FEV~1~, SGRQ, and exacerbation CIDs) over 6 months with FF/UMEC/VI single-inhaler triple therapy compared with the ICS/LABA budesonide/formoterol (communication at the European Respiratory Society International Congress 2017, Naya et al. Poster PA3248). The inconsistency between the observed reduction in SGRQ CID events in the prospective analysis of the FULFIL study and the current analysis suggests that the 3-month CID assessment period in the current analysis may have been too short in duration to fully evaluate this component. Similarly, the recent IMPACT study (NCT02164513) showed a significantly reduced rate of moderate or severe COPD exacerbations, as well as improved lung function and SGRQ scores, following 52 weeks of once-daily FF/UMEC/VI single-inhaler triple therapy compared with the ICS/LABA FF/VI or the LAMA/LABA UMEC/VI in patients with COPD with a history of prior exacerbations \[[@CR35]\]. The consistent improved stability observed for additional bronchodilation in all studies suggests a potential long-term benefit from improving lung function with two long-acting bronchodilators in symptomatic patients with COPD. Given that many patients fail to attain meaningful improvement in outcomes despite receiving pharmacological treatment, continued stability may be a useful treatment goal \[[@CR21]\].

There has been increasing interest in the use of the CID concept as an additional efficacy endpoint. Indeed, the CID concept has been employed in several studies over the past two years to compare disease stability and freedom from deterioration between different combination therapies \[[@CR21], [@CR23], [@CR34], [@CR36], [@CR37]\]. However, as this conceptual framework for assessing stability in COPD has only recently been developed, there is divergent methodology amongst different research groups regarding which components of deterioration should be included. The components included in this study (trough FEV~1~, SGRQ total score, and incidence of a moderate or severe exacerbation) were those included in the first study employing the CID endpoint \[[@CR22]\], and have been widely adopted by other researchers \[[@CR22], [@CR36], [@CR38]\]. The components were individually well-validated endpoints and were selected as they have been included in several long-term landmark trials \[[@CR15], [@CR16], [@CR30], [@CR31]\], thereby facilitating further analyses of the link between short-term CID assessment and increased future risks of mortality and severe exacerbations \[[@CR32], [@CR33]\]. Some follow-on studies have deviated from this CID approach to add a deterioration of ≥ 1 unit in the Transition Dyspnea Index focal score \[[@CR23]\], hospitalized exacerbations and death \[[@CR37], [@CR38]\], or all components \[[@CR34]\]. In some of these analyses, the original three-component CID definition was compared with these divergent definitions with no advantage being identified for the alternates \[[@CR22], [@CR38]\]. However, as assessing health status deterioration using the SGRQ component is impractical outside a clinical trial setting, replacing it with a health status deterioration measured using the simpler COPD Assessment Test (CAT) score has been shown to give very similar results \[[@CR39]\]. The current set of CID components (lung function, health status \[which can be measured by SGRQ or CAT score\] and exacerbations) fully align with the aims stated in the GOLD report for short-term monitoring of a patient's potential for future disease progression and assessing adequacy of current therapy \[[@CR1]\]. Inclusion of hospitalizations and death in the CID definition may reduce the CID endpoint usefulness as a monitoring tool to predict these events, an essential aim of the endpoint. Nevertheless, refinement of the CID concept and further research is required to maximize the utility of this endpoint.

While bronchodilator therapy is the mainstay of treatment for symptomatic patients with COPD, the potential for an early short-term increase in the risk of non-fatal cardiovascular events in the first month after initiating any new LAMA or LABA bronchodilator treatment cannot be excluded \[[@CR40]\]. In our integrated analysis, SAEs including cardiovascular events were numerically lower in patients receiving UMEC + ICS/LABA therapy than those receiving placebo + ICS/LABA. This highlights a likely favorable benefit:risk profile for additional bronchodilator therapy with UMEC, consistent with previous reports for UMEC therapy \[[@CR24], [@CR25], [@CR41], [@CR42]\].

A strength of this analysis is that it was based on four double-blind, placebo-controlled studies with robust replicate designs and high completion rates. In addition, the focus on all CID component events as well as the composite endpoint across multiple patient subgroups provides greater understanding of the utility of the composite CID endpoint overall. Potential limitations include the post hoc nature of the analysis, the fact that the GOLD classification used was based on the 2016 and not the 2018 report, and the short duration (12 weeks) of the trials, which may limit detection of differences between treatments in stability of SGRQ CID event, as previously discussed. In addition, the short duration of the trials prevented any analysis of the linkage between deterioration types. The 12-week treatment period also limited the number of patients likely to demonstrate a first exacerbation in all subgroups, especially as the populations enrolled were not enriched for a repeat exacerbation history on ICS/LABA therapy. Indeed only 7--9% of the 2016 GOLD Group D \[[@CR29]\] patient subgroup satisfied this more stringent 2018 GOLD Group D criteria \[[@CR1]\] based on exacerbation history only. The GOLD Group D subgroup analysis thereby focused predominantly on symptomatic patients with a FEV~1~ \< 50% predicted. Nevertheless, this analysis detected a high overall incidence of instability in these symptomatic patients with severe COPD on ICS/LABA therapy in a short treatment period. Finally, the results of this analysis cannot contribute to an understanding of the role of add-on ICS therapy in preventing a CID. This is an important issue due to the increasing interest in the use of dual and triple combination therapies in symptomatic patients \[[@CR36]--[@CR39], [@CR43], [@CR44]\].

Conclusions {#Sec18}
===========

Addition of UMEC to ICS/LABA therapy in patients with COPD with moderate-to-severe breathlessness (mMRC scores ≥ 2) reduced the risk of a first CID of any type by 45--58% compared with continued ICS/LABA therapy. The early benefit of additional bronchodilation with UMEC was observed in all patient types analyzed, and was predominantly driven by stabilizing lung function and reducing exacerbation risk, with no detrimental change in the overall safety profile. These findings provide further rationale for the need to optimize bronchodilator therapy in patients remaining symptomatic on ICS/LABA therapy, and may provide insights on the need for more structured monitoring of disease stability in symptomatic patients with COPD.
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